Microbial Community Composition in Explanted Cystic Fibrosis and Control Donor Lungs.
cystic fibrosis
disease
health
lung explant
microbiota (16S rRNA)
Journal
Frontiers in cellular and infection microbiology
ISSN: 2235-2988
Titre abrégé: Front Cell Infect Microbiol
Pays: Switzerland
ID NLM: 101585359
Informations de publication
Date de publication:
2021
2021
Historique:
received:
25
08
2021
accepted:
13
12
2021
entrez:
4
4
2022
pubmed:
5
4
2022
medline:
6
4
2022
Statut:
epublish
Résumé
To date, investigations of the microbiota in the lungs of people with Cystic Fibrosis (PWCF) have primarily focused on microbial community composition in luminal mucus, with fewer studies observing the microbiota in tissue samples from explanted lung tissue. Here, we analysed both tissue and airway luminal mucus samples extracted from whole explanted lungs of PWCF and unused donor lungs. We determined if the lung microbiota in end-stage CF varied within and between patients, was spatially heterogeneous and related to localized structural damage. Microbial community composition was determined by Illumina MiSeq sequencing and related to the CF-Computed Tomography (CT) score and features of end-stage lung disease on micro-CT. Ninety-eight CF tissue (n=11 patients), 20 CF luminal mucus (n=8 patients) and 33 donor tissue (n=4 patients) samples were analysed. Additionally, we compared 20 paired CF tissue and luminal mucus samples that enabled a direct "geographical" comparison of the microbiota in these two niches. Significant differences in microbial communities were apparent between the 3 groups. However, overlap between the three groups, particularly between CF and donor tissue and CF tissue and CF luminal mucus was also observed. Microbial diversity was lower in CF luminal mucus compared to CF tissue, with dominance higher in luminal mucus. For both CF and donor tissue, intra- and inter-patient variability in ecological parameters was observed. No relationships were observed between ecological parameters and CF-CT score, or features of end-stage lung disease. The end-stage CF lung is characterised by a low diversity microbiota, differing within and between individuals. No clear relationship was observed between regional microbiota variation and structural lung damage.
Identifiants
pubmed: 35368453
doi: 10.3389/fcimb.2021.764585
pmc: PMC8966769
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
764585Informations de copyright
Copyright © 2022 Einarsson, Vanaudenaerde, Spence, Lee, Boon, Verleden, Elborn, Dupont, Van Raemdonck, Gilpin, Vos, Verleden and Tunney.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
Sci Rep. 2015 May 14;5:10241
pubmed: 25974282
Lancet. 2014 Aug 23;384(9944):703-13
pubmed: 25152272
ISME J. 2014 Jun;8(6):1247-58
pubmed: 24401860
FEMS Immunol Med Microbiol. 2012 Jul;65(2):236-44
pubmed: 22211589
Ann Am Thorac Soc. 2014 Sep;11(7):1049-55
pubmed: 25072206
Nat Methods. 2010 May;7(5):335-6
pubmed: 20383131
Thorax. 2014 Mar;69(3):247-53
pubmed: 24127019
Thorax. 2018 May;73(5):481-484
pubmed: 28802277
Nat Methods. 2013 Oct;10(10):999-1002
pubmed: 23995388
PLoS One. 2011 Feb 22;6(2):e16384
pubmed: 21364979
Eur Respir J. 2018 Jul 11;52(1):
pubmed: 29946004
NPJ Biofilms Microbiomes. 2016 Dec 2;2:4
pubmed: 28649398
mSystems. 2019 Sep 24;4(5):
pubmed: 31551401
Pulm Med. 2012;2012:746358
pubmed: 22448327
Am J Respir Crit Care Med. 2016 Mar 1;193(5):516-26
pubmed: 26551917
Thorax. 2012 Oct;67(10):867-73
pubmed: 22707521
Cell Host Microbe. 2015 Sep 9;18(3):307-19
pubmed: 26299432
ISME J. 2012 Feb;6(2):471-4
pubmed: 21796216
Am J Respir Crit Care Med. 2013 May 15;187(10):1067-75
pubmed: 23491408
J Cyst Fibros. 2019 Nov;18(6):808-816
pubmed: 30905581
Am J Respir Crit Care Med. 2014 Feb 1;189(3):292-300
pubmed: 24354907
Proc Natl Acad Sci U S A. 2012 Apr 10;109(15):5809-14
pubmed: 22451929
Lancet Respir Med. 2018 Jun;6(6):461-471
pubmed: 29778403
PLoS One. 2012;7(4):e36313
pubmed: 22558432
Thorax. 2021 Mar;76(3):239-247
pubmed: 33268457
N Engl J Med. 2011 Oct 27;365(17):1567-75
pubmed: 22029978
Appl Environ Microbiol. 2006 Jul;72(7):5069-72
pubmed: 16820507
Proc Natl Acad Sci U S A. 2012 Aug 21;109(34):13769-74
pubmed: 22872870
Mod Pathol. 2019 Jun;32(6):817-829
pubmed: 30723292
Appl Environ Microbiol. 2007 Aug;73(16):5261-7
pubmed: 17586664
Nat Rev Microbiol. 2017 May;15(5):259-270
pubmed: 28316330
Bioinformatics. 2010 Oct 1;26(19):2460-1
pubmed: 20709691
J Thorac Imaging. 2006 Mar;21(1):14-21
pubmed: 16538150
Microbiome. 2015 Apr 01;3:12
pubmed: 25834733
Am J Respir Crit Care Med. 2011 Oct 15;184(8):957-63
pubmed: 21680950
JAMA. 2011 Jul 13;306(2):163-71
pubmed: 21750293
PLoS One. 2015 Jan 28;10(1):e0116029
pubmed: 25629612
Microbiome. 2020 Apr 2;8(1):45
pubmed: 32238195
PLoS Pathog. 2016 Aug 22;12(8):e1005846
pubmed: 27548479
Thorax. 2016 Sep;71(9):795-803
pubmed: 27146202
Bioinformatics. 2010 Jan 15;26(2):266-7
pubmed: 19914921
Mycopathologia. 2018 Feb;183(1):21-32
pubmed: 28762125
Thorax. 2018 Nov;73(11):1016-1025
pubmed: 30135091
J Cyst Fibros. 2018 Nov;17(6):687-689
pubmed: 30270113
Cell Host Microbe. 2017 Nov 8;22(5):705-716.e4
pubmed: 29056429
PLoS One. 2010 Jan 05;5(1):e8578
pubmed: 20052417